Dashyant Dhanak sold $206k of INCY
EVP & Chief Scientific Officer at INCYTE CORP. 2,419 shares at an average of $85.00, traded Jan 26, 2023, filed Jan 30, 2023.
Score components
- +15RoleOfficer
- +12Trade size$206k at market
- 0Share of holdings soldSold 4.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-005451, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 26, 2023 | SOpen-market sale Common Stock10b5-1 | -2,419 | $85.00 | $206k | 53,263 | Jan 30, 2023 |
Related signals
Other insiders at INCYTE CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $2.8M 23,218 shares | -11% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.4M 10,801 shares | -6% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.3M 10,803 shares | -5% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.3M 10,640 shares | -5% | |
| 1Weak | INCYTE CORP | Patrick A Mayes EVP & Chief Scientific Officer | $274k 2,207 shares | -3% | |
| 33Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $1.9M 15,888 shares | -7% | |
| 23Weak | INCYTE CORP | Patrick A Mayes EVP & Chief Scientific Officer | $5.7M 47,954 shares | -46% | |
| 15Weak | INCYTE CORP | Steven H Stein CMO & Head of Late-Stage Dev. | $215k 1,877 shares | -8% | |
| 14Weak | INCYTE CORP | Mohamed Khairie Issa EVP, Head of U.S. Commercial | $126k 1,093 shares | -2% | |
| 48Moderate | INCYTE CORP | Steven H Stein CMO & Head of Late-Stage Dev. | $3.2M 28,237 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.